HURA (TuHURA Biosciences) ROCE % : -157.53% (As of Sep. 2024)

View and export this data going back to 2024. Start your Free Trial

What is TuHURA Biosciences ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. TuHURA Biosciences's annualized ROCE % for the quarter that ended in Sep. 2024 was -157.53%.

TuHURA Biosciences ROCE % Historical Data

The historical data trend for TuHURA Biosciences's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TuHURA Biosciences ROCE % Chart

TuHURA Biosciences Annual Data

Trend

Dec21

Dec22

Dec23

ROCE %

-161.84

-447.61

TuHURA Biosciences Quarterly Data
	Dec21	Mar22	Dec22	Mar23	Dec23	Mar24	Jun24	Sep24
ROCE %	Get a 7-Day Free Trial			-767.98	-	-2,145.96	-304.15	-157.53

TuHURA Biosciences ROCE % Calculation

TuHURA Biosciences's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-29.298	/	( ( (15.197 - 2.872)	+	(4.362 - 3.596) )	/ 2 )
	=	-29.298	/	( (12.325	+	0.766)	/ 2 )
	=	-29.298	/	6.5455
	=	-447.61 %

TuHURA Biosciences's ROCE % of for the quarter that ended in Sep. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Sep. 2024 )		(Q: Jun. 2024 )		(Q: Sep. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Sep. 2024 )		(Q: Jun. 2024 )		(Q: Sep. 2024 )
	=	-8.836	/	( ( (14.093 - 4.758)	+	(4.14 - 2.257) )	/ 2 )
	=	-8.836	/	( ( 9.335	+	1.883 )	/ 2 )
	=	-8.836	/	5.609
	=	-157.53 %

(1) Note: The EBIT data used here is four times the quarterly (Sep. 2024) EBIT data.

TuHURA Biosciences (NAS:HURA) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

TuHURA Biosciences ROCE % Related Terms

Thank you for viewing the detailed overview of TuHURA Biosciences's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

TuHURA Biosciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TuHURA Biosciences Inc (NAS:HURA) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

10500 University Center Drive, Suite 110, Tampa, FL, USA, 33612

Website

https://www.tuhurabio.com

TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.